Leucovorin prescription rates increased steadily through August 2025, then increased sharply through November 2025. (HealthDay News) — For pediatric patients with autism spectrum disorder (ASD), ...

Retatrutide demonstrated substantial dose-dependent improvements in waist circumference and crucial cardiovascular risk factors, including non-HDL-C, triglycerides, systolic blood pressure, and ...

Investigators conducted a retrospective cohort study to assess the real-world impact of shifting from hormone replacement to natural cycle frozen embryo transfer.

Among patients with obesity, GLP-1 RAs were associated with a lower hazard of all-cause mortality and recurrence-free survival over a 10-year follow-up period. (HealthDay News) — Glucagon-like peptide ...

Patients have reportedly experienced classic Ebola disease symptoms like fever, headache, vomiting, severe weakness, abdominal pain, nosebleeds and vomiting blood, the CDC said.

Decrease seen in annualized asthma exacerbation rate overall and across asthma phenotypes and underrepresented populations ...

Pediatricians should emphasize multiple layers of drowning prevention; barriers limiting their use should be examined ...

Supported by phase 3 trial data showing significant SARA score improvements, levacetylleucine is on track to potentially become the first approved therapy for A-T.

In the phase 3 OCEANIC-STROKE trial, asundexian significantly reduced recurrent ischemic stroke risk compared with placebo without significantly increasing major bleeding. The Food and Drug ...

The primary outcome of postpartum hemorrhage occurred in 29.7 and 35.1% of the tranexamic acid and placebo groups, respectively. HealthDay News — Prophylactic tranexamic acid can prevent postpartum ...

Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

The sNDA for sevabertinib is supported by data from the SOHO-01 trial, showing a median duration of response of 11.0 months and a 71% objective response rate in patients with HER2-mutated NSCLC who ...